Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fred Hutchinson Cancer Center: Clinical Trials & FDA Approval Profile

Fred Hutchinson Cancer Center (Global / Institutional) sponsors 60 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 36 active protocols (24 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)23.3%
Median Closed Enrollment vs National (145 pts)40 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fred Hutchinson Cancer Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)60
Active Pipeline (Recruiting Now)36 (24)
Completed vs Stopped Early10 / 14 (23.3%)
Median Closed Actual Enrollment40 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fred Hutchinson Cancer Center
Hospital Research SiteLocationShared Protocols
Fred Hutch/University of Washington Cancer ConsortiumSeattle, WA56
Moffitt Cancer CenterTampa, FL7
City of Hope National Medical CenterDuarte, CA4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fred Hutchinson Cancer Center
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05952804IVIG for Infection Prevention After CAR-T-Cell TherapyPhase IIRECRUITING
NCT03779854Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor StePhase IIACTIVE NOT RECRUITING
NCT04965597Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 19Phase IICOMPLETED
NCT03870750Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or FrailPhase II/IIITERMINATED
NCT04706507Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and SepsisPhase IIITERMINATED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fred Hutchinson / UW Medicine across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Fred Hutchinson Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI